Tag: Anchiano Therapeutics
November 15, 2019
Anchiano Discontinues Phase 2 Codex Study
The company discontinued its Phase 2 Codex study evaluating the gene therapy inodiftagene vixteplasmid in bladder cancer. February 12, 2019
Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering
Anchiano Therapeutics (NASDAQ:ANCN) has announced it has priced its initial public offering of 2.65 million shares at a price of...
January 15, 2019